AbbVie (ABBV) announced positive topline results from the Phase 3, randomized, placebo-controlled, double-blind AFFIRM study evaluating the efficacy and safety of risankizumab

• The AFFIRM study results show significantly greater proportions of patients treated with risankizumab SC induction achieved the co-primary endpoints of Crohn's Disease Activity Index clinical remission and endoscopic response at week 12 compared to placebo
• Co-primary endpoints were percentage of participants with CDAI Clinical Remission and percentage of participants with endoscopic response at week 12

AbbVie's announcement of positive Phase 3 results for risankizumab is a significant development, suggesting strong efficacy in treating Crohn's Disease. This outcome is likely to bolster investor sentiment around ABBV's market potential, particularly within the biotech sector, and may influence its stock price positively as it indicates a promising therapeutic option ahead of potential regulatory reviews.